Audit: QRS - LSD for Health & Longevity
Audit conducted on 06/08/2026 08:32 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 91 |
| Passed | 81 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Spot-checked every populated span against the ER: doses (ER Therapeutic Protocol), timing, session structure, all 11 contraindications, all 11 interactions, all four benefit and risk tiers, all 10 biomarkers with targets and rationales, cadence, and all 8 qualitative markers all trace to ER text. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | No ER hedge is dropped or converted; the ER’s own tier grading carries the evidence-strength signal, and the QRS mirrors it exactly. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Absolute exclusions (lithium, MAOIs, psychotic/bipolar history, pregnancy and breastfeeding) stay in the Contraindications gate; caution-level items stay in Key Interactions. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Both gates draw exclusively from ER Key Interactions & Contraindications; Benefits from Expected Benefits; Risks from Potential Risks & Side Effects; Monitoring and Qualitative from Monitoring Protocol & Defining Success. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | The QRS contains no PMIDs, no NCT identifiers, no author or expert names, and no brand names (MM120, Delysid, etc. are not carried over). |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No sponsor, group, institution, or investigator is named anywhere in the sheet. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Neutral, evidence-forward register matching the ER, including its explicit separation of full-dose from low-dose evidence. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Benefits are presented first and by tier; risks and gates are stated as facts rather than warnings. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | No imperatives; monitoring entries describe what a measure establishes rather than instructing an action. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | Cadence and marker rows are descriptive of trial and ER practice, not directed at an individual. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No occurrence of “recommend”, “advise”, or “should” anywhere in the rendered text. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns present in the rendered body. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Terminology is at or below the ER’s own level; anhedonia, ECG, eGFR, TSH, hs-CRP, and ALT are expanded or glossed as in the ER. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Gate items, benefit tiers, and risk tiers are reduced to key-fact clauses; no elaborations or mechanistic rationale carried through. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed by full-text scan; no “you”, “your”, “we”, or “our”. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Baseline echocardiography, CYP2D6 genotyping, and a 12-hour supervised window are presented as ordinary expectations. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Preparatory meetings, two attendants, integration sessions, and multi-week medication washouts are retained. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | No simplification toward casual or recreational use; the supervised-session framing is preserved throughout. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | The At-A-Glance and Benefits tiers separate the well-supported supervised full-dose signal from the null low-dose signal that this audience is most likely to encounter. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | The string “anti-aging” does not appear; the page title uses “Health & Longevity”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | “Single oral dose”, “myocardial infarction”, “valvular regurgitation”, “hepatic impairment” are used rather than colloquial equivalents. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fixed strings verified verbatim at lines 446, 495, 546, 581, 614, 658, 693, 697–699, 869, and in every tier <strong> label. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | 72 data-qrs-var spans present, accounting for every variable region: header 4, at-a-glance 1, action 9, time 9, benefits 4, gates 2, risks 4, markers 30, cadence 1, qualitative 8. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | The non-variable website="evidence_review", website="audit", and website="full_review" spans and the footer disclaimer are untouched. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section is empty; every section mapped into the QRS carries content. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | All 8 Qualitative Assessment labels, the “Best time of day” protocol label, and all interaction-class labels reproduce the ER’s bold labels; monitoring row labels match the ER table verbatim. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Marker names, tier labels, and qualitative labels are all ER strings; the protocol cell labels summarise multi-bullet ER syntheses rather than renaming a single ER bullet. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | Full-text scan returns no emoji code points; tiering is carried by <strong> labels and the CSS palette. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is condensed to key-fact clauses against its per-section budget: gate items carry no rationale, benefit and risk tiers are single-clause lists, and the cadence paragraph compresses two ER paragraphs into one sentence group. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14; the comment opens on line 2 immediately after the doctype on line 1. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- on line 3, closing --- on line 13, with the descriptive text on line 2 preceding it. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; none of its values are repeated in the body except where the template independently requires them. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:04" is quoted, correctly, because it contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: lsd_2026-0806-0548_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0806-0819, correct format. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” is a single word with no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” is nickname plus version number with no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9: qrs_filename: lsd_2026-0806-0548_Opus_QRS.html, matching the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine keys; no stray whitespace and no unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “LSD for Health & Longevity - Quick Reference Sheet”, matching ER canonical_topic. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: “LSD for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: “08/06/2026”, the correct reformat of 2026-0806. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: “Opus 5”, matching the frontmatter. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header carries only the title and the template subline; the ER’s extensive “Also known as” list is not reproduced. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Lines 434–438 compress the ER Conclusion’s mechanism, strongest evidence, null low-dose finding, and practical limits. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 58 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each of the four sentences maps to a distinct clause of the ER Conclusion. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | Uses “full-strength sessions”, “dummy treatment”, “very small scheduled amounts” rather than full-dose, placebo, or microdosing; no acronyms present. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial name, year, sample size, or p-value appears. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No point estimates, confidence intervals, or effect sizes appear. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All 11 items trace to the ER’s “Populations who should avoid the intervention entirely” sub-list and its absolute-contraindication bullets. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All 11 ER exclusion bullets are present, none added and none dropped. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Lines 584–609: eleven discrete <li> elements inside the stop_items span. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Trailing rationale removed throughout, e.g. “given the reported lowering of seizure threshold” and “on the basis of absent safety data” are stripped from the seizure and pregnancy items. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | 140/90 mmHg thresholds, the 6-to-12-month infarction window, NYHA Class III or IV, Child-Pugh Class B or C, and the 12-hour window are all retained. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no bare ranking symbols inside parentheses in this section; severity is expressed in words. |
| 8.7 | If no [stop_items] are present the section is left empty | N/A | Eleven stop_items are present. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All 11 items trace to that ER section’s caution- and monitor-level bullets. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | Lithium and monoamine oxidase inhibitors are correctly held in the Contraindications gate and not duplicated here. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Lines 617–648: eleven discrete <li> elements inside the caution_items span. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Every ER “— caution”, “— monitor”, and “— interaction, therapeutic and blocking” suffix is stripped, along with all mechanism and mitigation prose. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Named drug lists retained for SSRIs/SNRIs, tricyclics, antipsychotics, CYP2D6 and CYP3A4 agents, OTC serotonergics, stimulants, and both supplement classes; only in-parens definitional glosses are trimmed. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s parentheses in this section contain drug names only; no ranking notation is used. |
| 9.7 | If no [caution_items] are present the section is left empty | N/A | Eleven caution_items are present. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells draw on ER Therapeutic Protocol bullets covering the full-dose, psycholytic, and low-dose models, timing, splitting, and setting. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Dose, best time of day, and session structure are the three decisions the ER treats as protocol-defining. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies well over three distinct actionable aspects; all three sets are populated. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine spans carry substantive ER-derived content; none is empty or placeholder. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Long-standing anxiety, alcohol misuse, and well-being/openness are the three outcomes for which the ER states an onset timescale. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Order follows the ER tiering: two High-tier benefits first, then the Medium-tier well-being and openness outcome. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct time-to-effect aspects are available and all three sets are populated. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine spans carry ER-derived content, including the ER’s note that anxiety benefit is measured at 4 and 16 weeks rather than on the day. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides time-to-effect information in Practical Considerations and Expected Benefits. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | Every listed benefit corresponds to an ER Expected Benefits subheading. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present at lines 548, 554, 561, and 568. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | No Magnitude figures, Cohen’s d values, confidence intervals, or “⚠️ Conflicted” markers carried through; each tier is a semicolon-separated list of key facts. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any of the four benefit spans. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four ER benefit tiers contain items, so no span needs to be hidden. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | Every listed risk corresponds to an ER Potential Risks & Side Effects subheading. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present at lines 660, 667, 674, and 681. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Incidence figures (92.5 percent, 0.6 percent, 3.8 percent), blood-pressure deltas, and mechanism prose are all stripped. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any of the four risk spans. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four ER risk tiers contain items, so no span needs to be hidden. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Rows reproduce the ER Monitoring Protocol & Defining Success biomarker table, including its “Why Measure It?” column text. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All 10 ER table rows present: blood pressure, resting heart rate, ECG, echocardiogram, ALT, eGFR, TSH, hs-CRP, prolactin, and CYP2D6 genotype, with targets verbatim. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Lines 856–863 condense the ER’s baseline, full-dose, and repeated low-dose cadences, including the 12-month and 12-to-24-month echocardiogram interval. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | All items come from the ER’s qualitative-marker bullet list in Monitoring Protocol & Defining Success. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All 8 ER qualitative markers are present with their bold labels verbatim, including the anhedonia gloss and the persisting-visual-phenomena stop signal. |
Issues 06/08/2026 08:32
Pass rate 100.00%. No issues found.
Issues 06/08/2026 08:27
- 1.1 — Durability presented as time to effect:
time_3_valuereads “12 months” under the “Time to effect” subhead (QRS line 532), implying the well-being and openness benefit takes twelve months to appear; the ER describes acute mood elevation with increases that remain measurable at twelve months (ER lines 205, 207).
Fixes 06/08/2026 08:27
- 1.1 — Durability presented as time to effect: Changed
time_3_valuefrom “12 months” to “Acute, sustained to 12 months” and prefixedtime_3_subwith “Mood elevation is acute.”, so the cell reflects the ER’s acute onset with twelve-month persistence rather than implying a twelve-month time to effect.